Strikingly, in vivo, AKR1C1 depletion renders cancer cells more sensitive to ferroptosis and synergizes with ferroptosis inducers to suppress tumor growth much more potently than either treatment alone (Fig. 7). This evidence concerns the gene AKR1C1 and neoplasm.